Advertisement

Topics

FDA Approves Amgen And Allergan’s Kanjinti Trastuzumab Biosimilar

04:04 EDT 14 Jun 2019 | SCRIP

Amgen and Allergan’s biosimilar version of Herceptin has been approved by the US Food and Drug Administration.

      

Related Stories

 

Original Article: FDA Approves Amgen And Allergan’s Kanjinti Trastuzumab Biosimilar

NEXT ARTICLE

More From BioPortfolio on "FDA Approves Amgen And Allergan’s Kanjinti Trastuzumab Biosimilar"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...